Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price […]
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price […]
